Reuters logo
BRIEF-Helix Biopharma Q2 loss per share C$0.03
March 17, 2017 / 12:29 PM / 9 months ago

BRIEF-Helix Biopharma Q2 loss per share C$0.03

March 17 (Reuters) - Helix Biopharma Corp -

* Announces fiscal second quarter 2017 results and closing of private placement

* Q2 loss per share C$0.03

* Helix Biopharma Corp - “Will require additional financing in near term and in future”

* Cash balance of C$1.4 million, as at Jan 31, 2017, is insufficient to meet anticipated cash needs for working capital,capital expenditures

* Decided to substitute vinorelbine/cisplatin combination study going forward with study combining l-DOS47 with pemetrexed/carboplatin Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below